[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634026":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":60,"collaborators":62,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":25,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":25,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":25,"overallStatus":86,"whyStopped":25,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Oklahoma","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Disulfiram","EXPERIMENTAL","Participants will receive disulfiram 250 mg orally once daily for 12 weeks in addition to stable background disease-modifying antirheumatic drug (DMARD) therapy.",[13],"Drug: Disulfiram (DSF)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive matching placebo orally once daily for 12 weeks in addition to stable background disease-modifying antirheumatic drug (DMARD) therapy.",[19],"Drug: Placebo",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Matching placebo will be administered orally once daily for 12 weeks. The placebo will be identical in appearance, packaging, and labeling to disulfiram to maintain blinding.",[15],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Disulfiram (DSF)","Disulfiram will be administered orally at a dose of 250 mg once daily for 12 weeks.",[9],[31],{"name":32,"affiliation":5,"role":33},"Beatriz Y Hanaoka, MD, MSc","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","405-271-3480","beatriz-hanaoka@ou.edu",{"name":40,"role":36,"phone":37,"phoneExt":25,"email":41},"Natalie Feland, MPH, BSN, RN","osctr@ou.edu",[43],{"facility":44,"status":25,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University of Oklahoma Health Campus","Oklahoma City","Oklahoma","73104","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-97.51643,35.46756,{"lat":54,"lon":53},[57,59],{"name":40,"role":36,"phone":37,"phoneExt":25,"email":58},"osctr@ouhsc.edu",{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":61,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[63],{"name":64,"class":6},"Presbyterian Health Foundation","100634026","phase-2-disulfiram-in-rheumatoid-arthritis-100634026",false,"NCT07534332","Disulfiram in Rheumatoid Arthritis","Therapeutic Targeting of Gasdermin D-Mediated Pyroptosis to Attenuate Joint Inflammation in Rheumatoid Arthritis","Inclusion Criteria:\n\nAge 18-75 years Body mass index (BMI) ≥25 kg\u002Fm² Diagnosis of rheumatoid arthritis (RA) according to ACR\u002FEULAR classification criteria Active disease defined as Clinical Disease Activity Index (CDAI) \\>10 Stable disease-modifying antirheumatic drug (DMARD) therapy for ≥3 months prior to enrollment Willingness to abstain from alcohol for the duration of the study Ability and willingness to comply with study procedures\n\n\\-\n\nExclusion Criteria:\n\nSignificant liver dysfunction (ALT or AST \\>2.5× upper limit of normal) Current or recent alcohol dependence (based on screening, e.g., AUDIT) Known hypersensitivity to disulfiram or other thiuram derivatives Pregnancy or breastfeeding Severe cardiovascular disease (e.g., myocardial infarction, arrhythmia, coronary occlusion) Severe psychiatric illness (e.g., psychosis, suicidal ideation) Neurologic disorders (e.g., epilepsy, peripheral neuropathy, cerebral damage) Chronic or acute renal disease (e.g., nephritis) Hepatic cirrhosis or hepatic insufficiency Use of contraindicated medications (e.g., metronidazole, phenytoin, paraldehyde, alcohol-containing preparations, warfarin) Other autoimmune diseases or active\u002Fchronic infections Diabetes mellitus or hypothyroidism Allergy to topical iodine Any condition that, in the opinion of the investigator, would pose undue risk or interfere with study participation","ALL","18 Years","75 Years",{"count":76,"type":77},20,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity.\n\nDisulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction.\n\nThis study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo.\n\nThe primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.",[83,84,85],"Rheumatoid Arthritis","Inflammation","Obesity","NOT_YET_RECRUITING","2026-04-24",{"date":89,"type":90},"2026-04-28","ACTUAL",{"date":92,"type":77},"2026-05",{"date":94,"type":77},"2028-04-30",{"name":5,"class":6},1]